Current trends in freeze-drying
Controlled nucleation is one of the most topical trends in the industry, as the freezing step is of paramount importance for stability of products. The temperature range between 0°C and the real...
View ArticleSir Andrew Witty to retire as CEO of GSK
GSK has announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017. Sir Andrew Witty CREDIT: GSK GSK’s Board has agreed that he will retire...
View ArticleGSK’s Advair Diskus achieves primary endpoint in LABA safety study
GSK has announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study. The VESTRI study compared Advair Diskus (FSC), a combination of the LABA, salmeterol, and the inhaled...
View ArticleGSK presents data on of Nucala in asthma patients stratified by eosinophil...
Data from a post-hoc study show that severe asthma patients with a baseline blood eosinophil count of 150 cells/μL or above who received GSK’s Nucala (100mg fixed dose subcutaneous injection of...
View ArticleMaternal immunisation
Childhood vaccination was one of the most significant medical success stories of the 20th century with vaccines making diseases such as measles, whooping cough and rubella much more unlikely. New and...
View ArticleCMA fines pharmaceutical companies £45 million
The UK Competition and Markets Authority (CMA) has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine. The CMA’s decision...
View ArticleGSK submits sBLA seeking expanded indication for Flulaval Quadrivalent
GSK has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Flulaval Quadrivalent (Influenza Vaccine). This vaccine is currently approved for...
View ArticlePresentation videos from the World’s 1st International Pharmaceutical seminar...
Videos of the presentations from the world’s 1st TRS seminar for quantitative pharmaceutical analysis can be viewed on demand at www.cobaltlight.com/trs100seminar. More than 70 delegates from across...
View ArticleGSK initiates Phase 1 study of IONIS-HBV-LRx; Ionis gets milestone payment
Ionis Pharmaceuticals has announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx. IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the...
View ArticleComic Relief and GSK team up to help fight malaria
Comic Relief and GSK are teaming up in support of global efforts to strengthen health systems’ capabilities to fight malaria. A new fund – created through a £17m donation from GSK and £5m from Comic...
View ArticleAmgen reacquires product rights to 3 products from GSK
Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries. The agreement...
View ArticlePhase III study of sirukumab in giant cell arteritis starts
Dosing has commenced in a Phase III study evaluating GSK’s sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA). GCA is a type...
View ArticleGSK announces Phase III results for belimumab in SLE
GSK has announced results from the BLISS-SC Phase III pivotal study of Benlysta (belimumab) administered subcutaneously in patients with active, autoantibody-positive systemic lupus erythematosus...
View ArticleGSK and Merck initiate Phase I trial of GSK3174998 with Keytruda
GSK and Merck have announced the initiation of a Phase I clinical trial designed to evaluate GSK’s GSK3174998 as monotherapy and in combination with Merck’s Keytruda (pembrolizumab) in patients with...
View ArticleGSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles, in adults aged 70 years and over. GlaxoSmithKline plc announced today that the second pivotal phase III study of its...
View ArticleGSK’s losmapimod cardiovascular study fails
GSK has announced that an interim review of data from part A of its losmapimod phase III study, LATITUDE-TIMI 60, did not indicate efficacy against the primary endpoint and did not support investment...
View ArticleCHMP recommends mepolizumab for severe refractory eosinophilic asthma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for GSK’s Nucala (mepolizumab) as an...
View ArticleResults from the SUMMIT COPD CV survival study announced
GlaxoSmithKline (GSK) and Theravance have announced initial results from the SUMMIT COPD study for Relvar/Breo Ellipta (fluticasone furoate/vilanterol or FF/VI) 100/25mcg. The study involved 16,485...
View ArticleMerial Sas, GSK, Sanofi Pasteur, Nestle Research Center will meet at the...
Microbiological contamination of products and processes continues to be a major concern to the pharmaceutical industry and its regulations. Contamination of an aseptic process can have a serious impact...
View ArticleNovartis pays $1 billion to bolster its pipeline with ofatumumab
Novartis is to acquire all remaining rights to ofatumumab from GSK for up to $1 billion plus royalties. Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for...
View Article